New blood test could end guesswork in liver cancer diagnosis
NCT ID NCT06342414
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study aims to develop a simple blood test that can tell the difference between two common types of liver cancer: hepatocellular carcinoma and cholangiocarcinoma. Researchers will analyze tiny particles called exosomes in the blood using machine learning. The goal is to help doctors choose the right treatment without needing a biopsy first. About 400 adults with confirmed liver cancer will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Graduate School of Medical Sciences, Kumamoto University
RECRUITINGKumamoto, Japan
-
Graduate School of Medical Sciences, Kyushu University
RECRUITINGFukuoka, Japan
-
Hokkaido University Graduate School of Medicine
RECRUITINGSapporo, Japan
-
Tokushima University
RECRUITINGTokushima, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver